Correlation Between Zenas BioPharma, and Septerna, Common
Can any of the company-specific risk be diversified away by investing in both Zenas BioPharma, and Septerna, Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zenas BioPharma, and Septerna, Common into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zenas BioPharma, Common and Septerna, Common Stock, you can compare the effects of market volatilities on Zenas BioPharma, and Septerna, Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zenas BioPharma, with a short position of Septerna, Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zenas BioPharma, and Septerna, Common.
Diversification Opportunities for Zenas BioPharma, and Septerna, Common
-0.37 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Zenas and Septerna, is -0.37. Overlapping area represents the amount of risk that can be diversified away by holding Zenas BioPharma, Common and Septerna, Common Stock in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Septerna, Common Stock and Zenas BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zenas BioPharma, Common are associated (or correlated) with Septerna, Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Septerna, Common Stock has no effect on the direction of Zenas BioPharma, i.e., Zenas BioPharma, and Septerna, Common go up and down completely randomly.
Pair Corralation between Zenas BioPharma, and Septerna, Common
Given the investment horizon of 90 days Zenas BioPharma, Common is expected to under-perform the Septerna, Common. But the etf apears to be less risky and, when comparing its historical volatility, Zenas BioPharma, Common is 1.01 times less risky than Septerna, Common. The etf trades about -0.14 of its potential returns per unit of risk. The Septerna, Common Stock is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest 1,800 in Septerna, Common Stock on September 12, 2024 and sell it today you would earn a total of 501.00 from holding Septerna, Common Stock or generate 27.83% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 52.38% |
| Values | Daily Returns |
Zenas BioPharma, Common vs. Septerna, Common Stock
Performance |
| Timeline |
| Zenas BioPharma, Common |
| Septerna, Common Stock |
Zenas BioPharma, and Septerna, Common Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Zenas BioPharma, and Septerna, Common
The main advantage of trading using opposite Zenas BioPharma, and Septerna, Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zenas BioPharma, position performs unexpectedly, Septerna, Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Septerna, Common will offset losses from the drop in Septerna, Common's long position.| Zenas BioPharma, vs. enGene Holdings Common | Zenas BioPharma, vs. GRI Bio | Zenas BioPharma, vs. Prime Medicine, Common | Zenas BioPharma, vs. Amylyx Pharmaceuticals |
| Septerna, Common vs. Dogwood Therapeutics, | Septerna, Common vs. Viking Therapeutics | Septerna, Common vs. Vanda Pharmaceuticals | Septerna, Common vs. Verrica Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Complementary Tools
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |